Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Inclusion Criteria:

• Women of childbearing potential must have a negative pregnancy test, cannot bebreastfeeding and must be willing to use contraception

• Willing to provide written informed consent and to comply with study requirements

• Histologically confirmed locally advanced or metastatic clear cell renal cellcarcinoma that has progressed during or after at least two prior therapeuticregimens which must include vascular endothelial growth factor (VEGF)-targetedtherapy and checkpoint inhibitor therapy or that has otherwise failed suchtherapies, is measurable disease per RECIST 1.1 criteria, is biopsy accessible

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

• Estimated life expectancy of longer than 3 months

• Adequate organ function at screening

Exclusion Criteria:

• History of untreated brain metastasis or leptomeningeal disease or spinal cordcompression

• Failure to recover from reversible effects of prior anti-cancer therapy

• Has received systemic therapy or radiation therapy within 2 weeks prior to firstdose

• History of solid organ or stem cell transplantation

• Current use of anti-VEGF or mammalian target of rapamycin (mTOR) agents, or chronicimmunosuppressive therapy

• Any prior use of hypoxia inducible factor 2 (HIF2) inhibitors within 6 months priorto first dose

• Current use of immune checkpoint inhibitors

• Use of an investigational agent or device within 2 weeks prior to dosing, or currentparticipation in an investigational study

• Known HIV, hepatitis B or hepatitis C

• History of other clinically meaningful disease

• Major surgery within 4 weeks of Screening

• Active malignancy requiring therapy other than ccRCC within 3 years of study entry

Note: Other eligibility criteria may apply per protocol.